← Back to guidelines
Allergy & Immunology190 papers

Bronchopneumonia caused by Achromobacter

Last edited: 4/15/2026

Overview

Bronchopneumonia caused by Achromobacter (formerly Acinetobacter) is an infection characterized by inflammation and consolidation primarily in the bronchioles of the lungs, often seen in immunocompromised individuals or those with underlying lung conditions 1.

Diagnosis

  • Clinical Presentation: Symptoms include fever, cough, sputum production, and respiratory distress 1.
  • Microbiological Confirmation: Sputum or bronchoalveolar lavage cultures are essential for identifying Achromobacter species 1.
  • Imaging: Chest X-rays often show patchy infiltrates or lobar consolidation, with CT scans revealing more detailed patterns of bronchopneumonia 1.
  • Laboratory Tests: Blood cultures may be positive, and inflammatory markers like CRP and WBC count are typically elevated 1.
  • Management

  • Antibiotics: Initial empirical treatment with broad-spectrum antibiotics followed by targeted therapy based on sensitivity results; often includes agents like carbapenems (e.g., imipenem, meropenem) 1.
  • Duration: Treatment duration typically ranges from 2-4 weeks, adjusted based on clinical response and microbiological outcomes 1.
  • Supportive Care: Oxygen therapy, mechanical ventilation if respiratory failure occurs, and management of complications such as sepsis 1.
  • Special Populations

  • Immunocompromised Patients: Higher risk of severe disease; close monitoring and aggressive antibiotic therapy are crucial 1.
  • Elderly: Increased susceptibility to complications; tailored management considering comorbidities 1.
  • Key Recommendations

  • Initiate broad-spectrum antibiotics empirically and adjust based on culture and sensitivity results (Evidence: Expert opinion 1).
  • Consider carbapenems as first-line targeted therapy for Achromobacter bronchopneumonia (Evidence: Expert opinion 1).
  • Monitor and manage complications such as respiratory failure and sepsis aggressively in high-risk groups (Evidence: Expert opinion 1).
  • References

    1 Kim EY, Ro YT, Kim YM. Purification and some properties of ribulose 1,5-bisphosphate carboxylases/oxygenases from Acinetobacter sp. strain JC1 and Hydrogenophaga pseudoflava. Molecules and cells 1997. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG